Cargando…

Efficacy and safety of tranexamic acid administration in traumatic brain injury patients: a systematic review and meta-analysis

BACKGROUND: The exacerbation of intracranial bleeding is critical in traumatic brain injury (TBI) patients. Tranexamic acid (TXA) has been used to improve outcomes in TBI patient. However, the effectiveness of TXA treatment remains unclear. This study aimed to assess the effect of administration of...

Descripción completa

Detalles Bibliográficos
Autores principales: Yokobori, Shoji, Yatabe, Tomoaki, Kondo, Yutaka, Kinoshita, Kosaku
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7333334/
https://www.ncbi.nlm.nih.gov/pubmed/32637122
http://dx.doi.org/10.1186/s40560-020-00460-5
_version_ 1783553730736553984
author Yokobori, Shoji
Yatabe, Tomoaki
Kondo, Yutaka
Kinoshita, Kosaku
author_facet Yokobori, Shoji
Yatabe, Tomoaki
Kondo, Yutaka
Kinoshita, Kosaku
author_sort Yokobori, Shoji
collection PubMed
description BACKGROUND: The exacerbation of intracranial bleeding is critical in traumatic brain injury (TBI) patients. Tranexamic acid (TXA) has been used to improve outcomes in TBI patient. However, the effectiveness of TXA treatment remains unclear. This study aimed to assess the effect of administration of TXA on clinical outcomes in patients with TBI by systematically reviewing the literature and synthesizing evidence of randomized controlled trials (RCTs). METHODS: MEDLINE, the Cochrane Central Register of Controlled Trials, and Igaku Chuo Zasshi (ICHUSHI) Web were searched. Selection criteria included randomized controlled trials with clinical outcomes of adult TBI patients administered TXA or placebo within 24 h after admission. Two investigators independently screened citations and conducted data extraction. The primary “critical” outcome was all-cause mortality. The secondary “important” outcomes were good neurological outcome rates, enlargement of bleeding, incidence of ischemia, and hemorrhagic intracranial complications. Random effect estimators with weights calculated by the inverse variance method were used to report risk ratios (RRs). RESULTS: A total of 640 records were screened. Seven studies were included for quantitative analysis. Of 10,044 patients from seven of the included studies, 5076 were randomly assigned to the TXA treatment group, and 4968 were assigned to placebo. In the TXA treatment group, 914 patients (18.0%) died, while 961 patients (19.3%) died in the placebo group. There was no significant difference between groups (RR, 0.93; 95% confidence interval, 0.86–1.01). No significant differences between the groups in other important outcomes were also observed. CONCLUSIONS: TXA treatment demonstrated a tendency to reduce head trauma-related deaths in the TBI population, with no significant incidence of thromboembolic events. TXA treatment may therefore be suggested in the initial TBI care.
format Online
Article
Text
id pubmed-7333334
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-73333342020-07-06 Efficacy and safety of tranexamic acid administration in traumatic brain injury patients: a systematic review and meta-analysis Yokobori, Shoji Yatabe, Tomoaki Kondo, Yutaka Kinoshita, Kosaku J Intensive Care Review BACKGROUND: The exacerbation of intracranial bleeding is critical in traumatic brain injury (TBI) patients. Tranexamic acid (TXA) has been used to improve outcomes in TBI patient. However, the effectiveness of TXA treatment remains unclear. This study aimed to assess the effect of administration of TXA on clinical outcomes in patients with TBI by systematically reviewing the literature and synthesizing evidence of randomized controlled trials (RCTs). METHODS: MEDLINE, the Cochrane Central Register of Controlled Trials, and Igaku Chuo Zasshi (ICHUSHI) Web were searched. Selection criteria included randomized controlled trials with clinical outcomes of adult TBI patients administered TXA or placebo within 24 h after admission. Two investigators independently screened citations and conducted data extraction. The primary “critical” outcome was all-cause mortality. The secondary “important” outcomes were good neurological outcome rates, enlargement of bleeding, incidence of ischemia, and hemorrhagic intracranial complications. Random effect estimators with weights calculated by the inverse variance method were used to report risk ratios (RRs). RESULTS: A total of 640 records were screened. Seven studies were included for quantitative analysis. Of 10,044 patients from seven of the included studies, 5076 were randomly assigned to the TXA treatment group, and 4968 were assigned to placebo. In the TXA treatment group, 914 patients (18.0%) died, while 961 patients (19.3%) died in the placebo group. There was no significant difference between groups (RR, 0.93; 95% confidence interval, 0.86–1.01). No significant differences between the groups in other important outcomes were also observed. CONCLUSIONS: TXA treatment demonstrated a tendency to reduce head trauma-related deaths in the TBI population, with no significant incidence of thromboembolic events. TXA treatment may therefore be suggested in the initial TBI care. BioMed Central 2020-07-03 /pmc/articles/PMC7333334/ /pubmed/32637122 http://dx.doi.org/10.1186/s40560-020-00460-5 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Yokobori, Shoji
Yatabe, Tomoaki
Kondo, Yutaka
Kinoshita, Kosaku
Efficacy and safety of tranexamic acid administration in traumatic brain injury patients: a systematic review and meta-analysis
title Efficacy and safety of tranexamic acid administration in traumatic brain injury patients: a systematic review and meta-analysis
title_full Efficacy and safety of tranexamic acid administration in traumatic brain injury patients: a systematic review and meta-analysis
title_fullStr Efficacy and safety of tranexamic acid administration in traumatic brain injury patients: a systematic review and meta-analysis
title_full_unstemmed Efficacy and safety of tranexamic acid administration in traumatic brain injury patients: a systematic review and meta-analysis
title_short Efficacy and safety of tranexamic acid administration in traumatic brain injury patients: a systematic review and meta-analysis
title_sort efficacy and safety of tranexamic acid administration in traumatic brain injury patients: a systematic review and meta-analysis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7333334/
https://www.ncbi.nlm.nih.gov/pubmed/32637122
http://dx.doi.org/10.1186/s40560-020-00460-5
work_keys_str_mv AT yokoborishoji efficacyandsafetyoftranexamicacidadministrationintraumaticbraininjurypatientsasystematicreviewandmetaanalysis
AT yatabetomoaki efficacyandsafetyoftranexamicacidadministrationintraumaticbraininjurypatientsasystematicreviewandmetaanalysis
AT kondoyutaka efficacyandsafetyoftranexamicacidadministrationintraumaticbraininjurypatientsasystematicreviewandmetaanalysis
AT kinoshitakosaku efficacyandsafetyoftranexamicacidadministrationintraumaticbraininjurypatientsasystematicreviewandmetaanalysis
AT efficacyandsafetyoftranexamicacidadministrationintraumaticbraininjurypatientsasystematicreviewandmetaanalysis